| Carbonxt Group Limited (CG1) ORDINARY FULLY PAID |
Materials |
$43 |
HY25 Results Announcement
|
28 Feb 2025 3:30PM |
$0.060 |
$0.100 |
risen by
66.67%
|
|
CG1 - Price-sensitive ASX Announcement
Full Release
Key Points
- Half year revenue of $7.4 million, down 13% on HY24.
- Pellet sales accounted for 47% of revenue and 33% of sales volume.
- Powdered Activated Carbon (PAC) accounted for 53% of revenue and showed a 13% increase.
- The Kentucky activated carbon plant achieved mechanical completion in December 2024.
- 1H25 gross margin improved to 49%, up from 44% in 1H24.
- Strategic focus on optimizing production and expanding market presence.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| HitIQ Limited (HIQ) ORDINARY FULLY PAID |
Health Care |
$11 |
Half Yearly Report and Accounts
|
28 Feb 2025 3:29PM |
$0.042 |
$0.021 |
fallen by
50%
|
|
HIQ - Price-sensitive ASX Announcement
Full Release
Key Points
- HITIQ's agreement with the Premier League was extended for 18 months with a 60% increase in annual contract value.
- Earl Eddings was appointed as Executive Chairman.
- Andrew Hart was appointed as Chief Financial Officer.
- HitIQ secured additional funding through a convertible note facility.
- The company announced a 2-year agreement with Westfield Sports High School for concussion management solutions.
- Second US patent approved for Nexus technology enhancing impact processing.
- The company reported a net loss of $3,090,932 for the half-year ended 31 December 2024.
- Cash reserves stood at A$661,004 as of 31 December 2024.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Carbonxt Group Limited (CG1) ORDINARY FULLY PAID |
Materials |
$43 |
Half Yearly Report and Accounts
|
28 Feb 2025 3:28PM |
$0.060 |
$0.100 |
risen by
66.67%
|
|
CG1 - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue decreased by 12.7% to $7,352,330.
- Net loss for the half-year was $4,209,461.
- Reduction in supply to a major customer due to plant outages affected revenues.
- There were no dividends paid during the financial period.
- Material uncertainty exists regarding the group's ability to continue as a going concern.
- The company is in discussions for additional funding and has plans for capital raising.
- The report includes a review of operations and financial results.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Grange Resources Limited (GRR) ORDINARY FULLY PAID |
Materials |
$318 |
Expansion of Savage River Operations
|
28 Feb 2025 3:28PM |
$0.225 |
$0.275 |
risen by
22.22%
|
|
| Enlitic Inc (ENL) CHESS DEPOSITARY INTERESTS 1:1 US PROHIBITED |
Health Care |
$15 |
Corporate Governance Statement & Appendix 4G
|
28 Feb 2025 3:27PM |
$0.095 |
$0.018 |
fallen by
81.05%
|
|
| Grange Resources Limited (GRR) ORDINARY FULLY PAID |
Materials |
$318 |
Appendix 4G
|
28 Feb 2025 3:27PM |
$0.225 |
$0.275 |
risen by
22.22%
|
|
| Grange Resources Limited (GRR) ORDINARY FULLY PAID |
Materials |
$318 |
Corporate Governance Statement
|
28 Feb 2025 3:26PM |
$0.225 |
$0.275 |
risen by
22.22%
|
|
| Bridge SaaS Limited (BGE) ORDINARY FULLY PAID |
Information Technology |
$5 |
Half Yearly Report and Accounts
|
28 Feb 2025 3:26PM |
$0.030 |
$0.024 |
fallen by
20%
|
|
BGE - Price-sensitive ASX Announcement
Full Release
Key Points
- Total revenue for the half-year was approximately $3.08 million.
- Net loss attributable to owners was $555,048, a 7.2% increase compared to last year.
- Acquisition of 51% interest in Brightside completed on 15 August 2024.
- Brightside demonstrated a 3% revenue increase and 17% gross profit growth.
- Bridge is exploring AI and robotics in the disability sector.
- No dividends were paid or declared during this financial period.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Enlitic Inc (ENL) CHESS DEPOSITARY INTERESTS 1:1 US PROHIBITED |
Health Care |
$15 |
Appendix 4E & 2024 Annual Report
|
28 Feb 2025 3:26PM |
$0.095 |
$0.018 |
fallen by
81.05%
|
|
ENL - Price-sensitive ASX Announcement
Full Release
Key Points
- 2024 revenue increased by 129.4% to $1,078,860.
- Loss after tax decreased slightly by 2.0% to $15,237,895.
- No dividends were paid or declared during the financial period.
- Enlitic acquired Laitek, enhancing data migration services.
- Ensight 2.0 was released, improving data quality and workflows.
- The company signed 16 new agreements with healthcare providers and vendors.
- Focus on reducing time to deployment for newly signed contracts.
- The report outlines a commitment to AI-driven healthcare transformation.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Ovanti Limited (OVT) ORDINARY FULLY PAID |
Communication Services |
$20 |
Half Yearly Report and Accounts
|
28 Feb 2025 3:24PM |
$0.008 |
$0.003 |
fallen by
62.50%
|
|
OVT - Price-sensitive ASX Announcement
Full Release
Key Points
- Loss for the consolidated entity amounted to $4,734,891.
- Revenue from ordinary activities decreased by 37% to $2,075,144.
- The loss includes an impairment of $1,681,947 related to an investment in 1-Destinasi Sdn Bhd.
- No dividends were paid, recommended, or declared during the current financial period.
- The company appointed EAS Advisors for its USA BNPL expansion plans.
- A $6 million placement was completed to fund expansion efforts.
- The company is under investigation for potential fund misappropriation.
- Directors believe the company can continue as a going concern.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| MAAS Group Holdings Limited (MGH) ORDINARY FULLY PAID |
Industrials |
$2,019 |
Results of 2025 Extraordinary General Meeting
|
28 Feb 2025 3:24PM |
$3.815 |
$5.550 |
risen by
45.48%
|
|
| The Calmer Co International Limited (CCO) ORDINARY FULLY PAID |
Consumer Staple |
$9 |
Half Year Results Presentation
|
28 Feb 2025 3:21PM |
$0.006 |
$0.003 |
fallen by
50%
|
|
CCO - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenues tripled to $4.36 million in H1 compared to H1 FY24.
- Net loss of $2.35 million due to marketing investments.
- Daily sales tracking at $25,000 per day.
- Gross profit margin of 52% achieved.
- Inventory levels increased by 58% to over $2 million.
- Net cash used in operations reduced by 50% in Q2 to $142,000 per month.
- Retail sales in Australia grew by 50% without advertising spend.
- Expansion into 846 Coles stores and 22 Quikstop convenience stores.
- Significant growth in the US market for kava products.
- Focus on cost control and operational efficiency.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Grange Resources Limited (GRR) ORDINARY FULLY PAID |
Materials |
$318 |
Grange Full Yr Statutory Accts 12 Months Ended 31 Dec 2024
|
28 Feb 2025 3:20PM |
$0.225 |
$0.275 |
risen by
22.22%
|
|
| The Calmer Co International Limited (CCO) ORDINARY FULLY PAID |
Consumer Staple |
$9 |
Half Yearly Report and Accounts
|
28 Feb 2025 3:19PM |
$0.006 |
$0.003 |
fallen by
50%
|
|
CCO - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue for H1 FY25 was AU$4.36M, up 206% YoY.
- Net loss reported at AU$2.35M due to inventory buildup and ad spend.
- eCommerce sales accounted for 70% of total revenue.
- The company aims to expand into the US functional beverage markets.
- Strong growth in eCommerce customer acquisition, increasing by 600%.
- Taki Mai Kava Shots now available in over 500 stores in Australia.
- Cash position as of 31 December 2024 was AU$2.16M.
- Plans for launching flavored RTD shots in the USA by April 2025.
- Received an offer from the Fiji Development Bank for AU$1.8M to support facility acquisition.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Grange Resources Limited (GRR) ORDINARY FULLY PAID |
Materials |
$318 |
Grange Resources Appendix 4E - 31 December 2024
|
28 Feb 2025 3:18PM |
$0.225 |
$0.275 |
risen by
22.22%
|
|
GRR - Price-sensitive ASX Announcement
Full Release
Key Points
- Announcement date is 5 February 2024
- Company is Grange Resources Limited
- Revenue decreased by 15% from $614,744,000 to $520,805,000
- Profit after tax decreased by 61% from $150,104,000 to $58,549,000
- Net tangible asset backing per share increased from $0.89 to $0.92
- Financial report audited by PricewaterhouseCoopers
- No significant post-reporting matters affecting operations
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Brightstar Resources Limited (BTR) ORDINARY FULLY PAID |
Materials |
$357 |
Half Year Accounts
|
28 Feb 2025 3:17PM |
$0.020 |
$0.505 |
risen by
2,489.74%
|
|
| Invion Limited (IVX) ORDINARY FULLY PAID |
Health Care |
$8 |
Appendix 4D and Half Year Financial Report
|
28 Feb 2025 3:16PM |
$0.140 |
$0.093 |
fallen by
33.57%
|
|
IVX - Price-sensitive ASX Announcement
Full Release
Key Points
- Invion Limited reported a loss of $1,872,230 for the half-year ended 31 December 2024.
- No revenue was recognized during the reporting period.
- The company is in discussions to expand rights to the Photosoft™ technology.
- A Phase II prostate cancer trial was successfully completed.
- A Phase I/II trial for non-melanoma skin cancer was initiated.
- Invion remains focused on advancing its clinical programs.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Antipa Minerals Limited (AZY) ORDINARY FULLY PAID |
Materials |
$384 |
Ceasing to be a substantial holder
|
28 Feb 2025 3:16PM |
$0.350 |
$0.580 |
risen by
65.71%
|
|
| DomaCom Limited (DCL) ORDINARY FULLY PAID |
Financials |
- |
Delay in Lodgement of Appendix 4D and HY Financial Report
|
28 Feb 2025 3:15PM |
$0.011 |
$0.011 |
fallen by
0%
|
|
| Tasmea Limited (TEA) ORDINARY FULLY PAID |
Industrials |
$1,090 |
Change of Director's Interest Notice - Stephen Young
|
28 Feb 2025 3:13PM |
$2.930 |
$4.190 |
risen by
43%
|
|
| Inventis Limited (IVT) ORDINARY FULLY PAID |
Industrials |
- |
Half Year Accounts
|
28 Feb 2025 3:13PM |
$0.024 |
$0.010 |
fallen by
58.33%
|
|
IVT - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue for the half year is $4,864,289, down 38% from last year.
- Loss from continuing operations is $1,731,631, an increase of 84.68%.
- Net loss for the period is $1,840,028, a 96.24% increase in losses.
- No interim dividend has been recommended.
- Directors are confident in meeting operational funding requirements for at least 12 months.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| BSA Limited (BSA) ORDINARY FULLY PAID |
Industrials |
$11 |
BSA unsuccessful in new NBN Co Field Module contract bid
|
28 Feb 2025 3:12PM |
$0.094 |
$0.150 |
risen by
59.57%
|
|
BSA - Price-sensitive ASX Announcement
Full Release
Key Points
- BSA Limited was unsuccessful in the new NBN Co Field Module contract bid.
- The tender was pursued in teaming with UGL.
- The existing nbn Unified Field Operations contract remains in place until 30 September 2025.
- Current contract volumes are stable and do not have guarantees.
- The contract comprises around 80% of BSA's revenue for FY2024.
- BSA is evaluating strategic options to mitigate the impact of losing the tender.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Imagion Biosystems Limited (IBX) ORDINARY FULLY PAID |
Health Care |
$13 |
Appendix 4E and 2024 Financial Report
|
28 Feb 2025 3:11PM |
$0.018 |
$0.026 |
risen by
48.57%
|
|
IBX - Price-sensitive ASX Announcement
Full Release
Key Points
- Imagion Biosystems Limited reported a loss of $2,066,957 for 2024, significantly lower than the previous year's loss.
- The company raised $3 million in December 2024 for advancing its MagSense® technology.
- A licensing agreement was signed with Biosensis for the production and sale of PrecisionMRX® nanoparticles.
- The clinical development of the MagSense® HER2 imaging agent is resuming, with an FDA application planned for 2025.
- The financial statements were audited and received an unmodified opinion.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| TrivarX Ltd (TRI) ORDINARY FULLY PAID |
Health Care |
$23 |
Appendix 4D & Half-Year Financial Report to 31 December 2024
|
28 Feb 2025 3:11PM |
$0.016 |
$0.020 |
risen by
25%
|
|
TRI - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue increased to $1,128,701 from $21,391 year-over-year.
- Net loss improved to $91,083 compared to a loss of $1,085,503 in the previous year.
- MEB-001, an AI-backed mental health screening algorithm, is progressing towards FDA approval.
- The company anticipates raising further capital for ongoing operations.
- TrivarX has strengthened its leadership team with new appointments.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Genetic Signatures Limited (GSS) ORDINARY FULLY PAID |
Health Care |
$56 |
Notification of cessation of securities - GSS
|
28 Feb 2025 3:10PM |
$0.555 |
$0.245 |
fallen by
55.86%
|
|
Call 1300 880 160
Start a chat
Schedule a call
